Gossamer Bio - GOSS STOCK NEWS

Gossamer Bio (NASDAQ: GOSS) presented clinical and preclinical data for seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress in Rio de Janeiro, Brazil. The presentations included one oral presentation and three posters focusing on seralutinib, an inhaled PDGFR, CSF1R and c-KIT inhibitor being developed for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The posters covered preclinical models demonstrating synergistic potential with sotatercept, sustained benefits observed in the TORREY open-label extension study, and the drug's sustained effect on circulating biomarkers.

Gossamer Bio (NASDAQ: GOSS) announced presentations of clinical and preclinical data for seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress in Rio de Janeiro. The company will showcase one oral and three poster presentations highlighting seralutinib's potential in treating pulmonary arterial hypertension (PAH).

Key highlights include preclinical evidence demonstrating synergistic effects when combining seralutinib with sotatercept, a recently approved PAH therapy. The company's ongoing global Phase 3 PROSERA Study allows for patient enrollment on stable sotatercept background treatment and permits other enrolled patients to add sotatercept after 24 weeks where approved.

The presentations will feature data from preclinical models, post-hoc analysis of the TORREY open-label extension, and sustained effects on circulating biomarkers, building upon positive Phase 2 TORREY Study results where most patients were on triple background PAH therapy.

Gossamer Bio (GOSS) has announced the approval of inducement grants to three non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The Compensation Committee approved non-qualified stock options to purchase up to 225,000 shares of common stock, effective January 6, 2025.

The options have an exercise price of $1.09 per share, matching the closing price of Gossamer's stock on Nasdaq Global Select Market on January 6, 2025. These ten-year options will vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, contingent on continued employment.

Gossamer Bio (Nasdaq: GOSS) announced that its Compensation Committee approved stock option grants to two new non-executive employees under the 2023 Employment Inducement Incentive Award Plan. The grants total 183,000 shares with an exercise price of $0.88 per share, matching Nasdaq's closing price on November 8, 2024. The options have a ten-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.

Gossamer Bio (GOSS) reported Q3 2024 financial results with $327.0 million in cash and equivalents as of September 30, 2024. The company posted revenue of $9.5 million from collaborator contracts, R&D expenses of $34.9 million, and a net loss of $30.8 million ($0.14 per share). The company expects current funds to sustain operations into H1 2027.

The company continues enrollment in the PROSERA Study, a Phase 3 trial for seralutinib in PAH patients, with topline results expected in Q4 2025. Additionally, Gossamer plans to initiate a Phase 3 trial for PH-ILD treatment in mid-2025.

Gossamer Bio, a clinical-stage biopharmaceutical company, announced the approval of non-qualified stock option awards for five new non-executive employees. The Compensation Committee of Gossamer's Board of Directors granted options to purchase up to 221,000 shares of the company's common stock under the 2023 Employment Inducement Incentive Award Plan. These awards, granted on October 4, 2024, are in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $1.07 per share, equal to the closing price of Gossamer's common stock on the grant date. They have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 monthly installments, subject to continued employment.

Gossamer Bio (Nasdaq: GOSS) announced data presentations for seralutinib at the European Respiratory Society (ERS) Congress 2024 in Vienna. The presentations include additional findings from the Phase 2 TORREY open-label extension study, highlighting sustained effects of seralutinib beyond 24 weeks in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The data demonstrates continued improvement in clinical outcome measures and sustained effects on circulating biomarkers relevant to PAH pathogenesis. Two oral presentations and one poster presentation will showcase seralutinib's potential in making a meaningful difference for patients with pulmonary hypertension.

Gossamer Bio (GOSS) reported strong Q2 2024 financial results, highlighting a cash position of $354.5 million as of June 30, 2024. The company's focus remains on developing seralutinib for PAH and PH-ILD treatment. Key developments include:

1. Ongoing enrollment in the PROSERA Study, a Phase 3 trial for PAH, with topline results expected in Q4 2025.
2. Plans to start a Phase 3 trial for PH-ILD in mid-2025.
3. A collaboration with Chiesi Group for seralutinib development and commercialization.
4. Q2 revenue of $95.9 million, including $88.8 million from license sales.
5. Net income of $49.2 million, or $0.22 per share, compared to a net loss in Q2 2023.

The company expects its current cash position to fund operations into the first half of 2027.

Gossamer Bio (Nasdaq: GOSS), a clinical-stage biopharmaceutical firm, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee of Gossamer's Board approved non-qualified stock options for a new non-executive employee, effective June 5, 2024. The grant includes options to purchase up to 170,000 shares at an exercise price of $0.57 per share, equivalent to the closing price on the Nasdaq Global Select Market on that date. These options have a ten-year term and will vest over four years: 25% after one year, with the remaining shares vesting in 36 monthly installments. These inducement awards aim to attract new talent under Gossamer's 2023 Employment Inducement Incentive Award Plan.